antiviral news
Press Releases in the global landscape
Sep 18, 2024
Common diabetes drug linked to lower rate of long COVID
The new findings come from the ongoing RECOVER trial and build on results seen in a 2023 trial.
Read More »
Sep 17, 2024
Use of metformin in adults with diabetes linked to lower risk of long COVID
The findings, published in the journal Diabetes Care, were based on health data from millions of U.S. patients and could have broader implications for the use of metformin in long COVID prevention generally.
Read More »
Sep 16, 2024
Cardiovascular risks of COVID-19 antivirals
Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful consideration when prescribing these drugs to high-risk patients.
Read More »
Sep 13, 2024
Atea stock drops as COVID-19 therapy fails in late-stage trial
Atea stock drops as COVID-19 therapy fails in late-stage trial.
Read More »
Sep 13, 2024
Atea ends development of inhibitor candidate as Covid-19 treatment following trial fail
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase inhibitor, which it was investigating as a Covid-19 treatment.
Read More »
Sep 13, 2024
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19.
Read More »